Citation Impact
Citing Papers
New β-Lactam–β-Lactamase Inhibitor Combinations
2020
Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?
2018
Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review
2023 Standout
Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant <em>Enterobacteriaceae</em>
2018
Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review
2019 Standout
Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy
2017
Treatment of Infections Due to MDR Gram-Negative Bacteria
2019
Development and Research Progress of Anti-Drug Resistant Bacteria Drugs
2021
Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology
2020
Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options
2019
Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research
2019
<p>Antimicrobial Resistance: Implications and Costs</p>
2019 Standout
Bacterial Antibiotic Resistance: The Most Critical Pathogens
2021 Standout
The role of new β-lactamase inhibitors in gram-negative infections
2019
Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem‐resistant Enterobacteriaceae
2018
Management of the Obstetric Patient with Status Asthmaticus
2008
Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID 19 en establecimientos de atención de la salud. Recomendaciones basadas en consenso de expertos e informadas en la evidencia
2020 Standout
Antimicrobial Resistance in ESKAPE Pathogens
2020 Standout
Works of Patrick McLeroth being referenced
Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections
2017
Status asthmaticus: a large MICU experience
2002
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1
2017
A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study)
2018
Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection
2016